Evidence map›Paper›PMID 42137511›Full record

ArticlePerspectives in clinical research

Patterns of adverse drug reactions and treatment outcomes in drug-resistant tuberculosis: A retrospective study from a tertiary care hospital in Delhi.

Amit Kamboj, Kshitij Agarwal, Rekha Rao, Minakshi Garg

Abstract read
In one paragraph

Article in Perspectives in clinical research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amit KambojDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
Kshitij AgarwalDepartment of Respiratory Medicine, University College of Medical Sciences (University of Delhi) and Guru Teg Bahadur Hospital, Delhi, India.
Rekha RaoDepartment of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India.
Minakshi GargDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant global health challenges with high mortality risks. Adverse drug reactions (ADRs) further complicate treatment, impacting patient adherence and outcomes. In India, the DOTS strategy under the Revised National Tuberculosis Control Programme has been widely implemented, yet TB management is hindered by limited patient awareness, socioeconomic constraints, and gaps in healthcare provider training. This study assesses the incidence of ADRs and their impact on treatment outcomes at a tertiary care hospital in Delhi. Materials and Methods: A cross-sectional study was conducted using retrospective medical record reviews of MDR-TB and XDR-TB patients (aged ≥18 years) registered at a university hospital in Delhi from January 2017 to August 2021. Data on ADRs and treatment outcomes were extracted from outpatient records for analysis. Results: Of 213 enrolled patients, 183 were analyzed, with 72.6% experiencing at least one ADR. Males had a higher ADR incidence (58%) than females (42%). The most common ADRs were gastrointestinal disorders (21.8%), eye disorders (14.3%), and musculoskeletal disorders (14.3%), primarily linked to pyrazinamide, ethambutol, and ethionamide. Serious ADRs occurred in 17.4% of cases. Conclusion: Gastrointestinal disorders, particularly nausea and vomiting, emerged as the most commonly reported ADRs. These findings emphasize the importance of early identification of high-risk patients and the need for close monitoring throughout anti-TB treatment to support adherence and improve outcomes. This study adds valuable evidence to strengthen pharmacovigilance efforts and inform the optimization of MDR/XDR-TB treatment protocols within India's public healthcare system.

Indexed as

Adverse drug reactionCausalitymultidrug-resistant tuberculosispreventability assessmentseverity

Identifiers

PMID42137511
PMCPMC13171125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.